Skip to main content

Table 3 Univariate Cox proportional hazard regression analysis for overall survival and relapse-free survival in stage I and II osteosarcoma patients

From: The PARP inhibitor olaparib potentiates the effect of the DNA damaging agent doxorubicin in osteosarcoma

Characteristics

No.

OS

P

RFS

P

HR (95% CI)

HR (95% CI)

Age, yr., ≥ 30 (vs. <  30)

8/30

1.785 (0.535–5.959)

0.346

2.491 (0.860–7.211)

0.092

Sex, male (vs. female)

20/30

1.428 (0.383–5.331)

0.596

1.939 (0.532–7.065)

0.316

Tumor size, cm, >  8 (vs. ≤ 8)

12/30

1.194 (1.037–1.374)

0.014

2.628 (0.901–7.662)

0.077

Stage, II (vs. I)

19/30

8.998 (1.158–69.931)

0.036

10.325 (1.347–79.152)

0.025

Histological grade, high (vs. low)

19/30

8.998 (1.158–69.931)

0.036

10.325 (1.347–79.152)

0.025

PARP1, positive (vs. negative)

21/30

6.780 (0.872–52.737)

0.067

7.310 (0.954–56.000)

0.055

γH2AX, positive (vs. negative)

17/30

15.788 (2.013–123.838)

0.009

8.414 (1.847–38.322)

0.006

BRCA1, positive (vs. negative)

14/30

4.428 (1.193–16.439)

0.026

6.323 (1.745–22.916)

0.005

BRCA2, positive (vs. negative)

11/30

4.372 (1.297–14.734)

0.017

2.898 (0.982–8.554)

0.054

CSddrm, score 3–4 (vs. score 0–2)

14/30

30.043 (3.724–242.374)

0.001

27.986 (3.501–223.717)

0.002

  1. OS overall survival, RFS relapse-free survival, HR hazard ratio, 95% CI 95% confidence interval, CSddrm the combined score for the immunohistochemical expression of PARP1, γH2AX, BRCA1, and BRCA2